Strategic funding Leverage the recent ARPA-H award of 46M to open conversations around collaboration, co-development, or funded pilot programs in blood cancer therapies and related diagnostic imaging partnerships.

Clinical collaboration Target academic medical centers and research collaborations already engaged with Ivy Brain Tumor Center and Insightec to explore non-invasive MR-guided ultrasound platforms combined with ALA-based therapies for rapid pilot studies.

Non-invasive focus Position as a preferred partner for hospitals seeking non-invasive therapeutic options for recurrent glioblastoma and other deadly cancers, highlighting MRI-guided focused ultrasound integration with drug formulations.

Early-stage readiness Engage biopharma and contract development organizations on ADC or combination therapy development opportunities, emphasizing clinical-stage credentials and potential for first-in-class treatment to accelerate IND/enrollment paths.

Global tech fit Propose data and infrastructure collaborations around cloud-based imaging analytics, MRI data integration, and scalable manufacturing/compliance for clinical trials to support multi-site trials and regulatory submissions.